Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling

Conclusions A DPP-4 inhibitor may be a novel therapeutic agent against the exercise intolerance seen in HF patients by improving the mitochondrial biogenesis in their skeletal muscle.

Source: Cardiovascular Research - August 23, 2016 Category: Cardiology Authors: Takada, S., Masaki, Y., Kinugawa, S., Matsumoto, J., Furihata, T., Mizushima, W., Kadoguchi, T., Fukushima, A., Homma, T., Takahashi, M., Harashima, S., Matsushima, S., Yokota, T., Tanaka, S., Okita, K., Tsutsui, H. Tags: Integrative physiology and pathophysiology Source Type: research